Key result
Benfotiamine supplementation for three months significantly decreased the corrected QT interval, QT dispersion, and spatial QRS-T angle in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy.
Why the study?
The significance of cardiac autonomic neuropathy has not been fully appreciated and there is no unified treatment algorithm.
Does benfotiamine improve the corrected QT interval, QT dispersion, and spatial QRS-T angle in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy?
RCT (n=32)
No
Does benfotiamine improve the corrected QT interval, QT dispersion, and spatial QRS-T angle in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy?
Benfotiamine supplementation may improve ECG markers of repolarization heterogeneity in patients with diabetic cardiac autonomic neuropathy.
Benfotiamine may improve repolarization markers in diabetic CAN; hypothesis-generating and requires randomized confirmation before practice change.
The significance of cardiac autonomic neuropathy (CAN) has not been fully appreciated and there is no unified treatment algorithm. Aim: To investigate the effects of benfotiamine (BFT) on the corrected QT interval (QTc), QT dispersion (QTd) and spatial QRS-T angle in patients with type 2 diabetes mellitus (T2DM) and CAN. 32 patients with T2DM and definite stage of CAN were allocated to two treatment groups: control (n = 15) received standard antihyperglycemic therapy; group 2 (n = 17) - in addition BFT 300 mg/d for three months. The QTc interval, QTd and spatial QRS-T angle parameters were analyzed. It was found out that BFT contributed to decrease of the QTc, QTd and QRS-T angle. The positive influences of BFT suggests the feasibility of its administration to patients with T2DM and definite stage of CAN. Obtained results suggest that the efficacy of BFT is the result of a direct effect of the BFT on the investigated indexes.
No takes yet. Share an insight, caveat, or question.
Serhiyenko et al. (2022) conducted an RCT in Type 2 diabetes mellitus and cardiac autonomic neuropathy (n=32). Benfotiamine vs. Standard antihyperglycemic therapy was evaluated on Corrected QT interval (QTc) in ms (p=<0.01). Benfotiamine supplementation for three months significantly decreased the corrected QT interval, QT dispersion, and spatial QRS-T angle in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: